Peptide half-life basics: why dosing schedules vary
Dosing frequency isn’t arbitrary — it follows the pharmacokinetics of each compound.
TL;DR
- Half-life is the time it takes for the concentration of a compound in the body to fall by 50% — it determines how often a peptide needs to be dosed.
- Short-acting peptides like ipamorelin have half-lives measured in minutes, requiring daily or multiple-daily injections to maintain effect.
- Modified peptides like CJC-1295 with DAC have half-lives of approximately 6 to 8 days, shifting the dosing schedule to once or twice weekly.
What it is
Half-life (t½) is a pharmacokinetic concept: the time required for the plasma concentration of a compound to decrease by half from its peak. It is one of the most fundamental parameters in clinical pharmacology — it tells a clinician how quickly a drug is cleared and therefore how often it needs to be administered to maintain a target concentration.
For most unmodified peptides, half-life is short. The body recognizes peptide bonds and breaks them down via circulating enzymes called peptidases. A peptide injected subcutaneously may reach peak concentration within 15 to 30 minutes and be largely cleared within an hour or two.
How it works
The half-life equation has a direct clinical consequence: a compound with a 30-minute half-life dosed once drops to 12.5% of its peak concentration within 90 minutes. A compound with a 7-day half-life dosed once still maintains roughly 50% of its peak one week later.
CJC-1295 illustrates the contrast well. The base molecule, CJC-1295 without DAC, has a half-life in the range of 30 minutes. Adding a Drug Affinity Complex (DAC) — a technology that allows the molecule to bind to albumin in the bloodstream — extends the half-life to approximately 6 to 8 days, as reported in a pharmacokinetic study in healthy adults (Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006). That single modification changes the dosing schedule from daily to weekly or biweekly.
Who asks about it
This topic matters to anyone who has looked at a peptide protocol and wondered why ipamorelin is dosed nightly while CJC-1295 with DAC is dosed weekly, or why some protocols call for multiple daily injections. The answer is always half-life and the target concentration curve the clinician is trying to maintain.
What the research says
The Teichman et al. 2006 study in the Journal of Clinical Endocrinology & Metabolism remains the primary pharmacokinetic reference for CJC-1295 with DAC in humans. The study reported sustained GH elevation following a single dose, with a half-life of approximately 6 to 8 days, supporting once or twice weekly dosing intervals.
For ipamorelin specifically, published pharmacokinetic data from animal studies reports half-lives in the range of 2 hours, with human pharmacokinetic data referenced in Raun et al., 1998 (Raun et al., European Journal of Endocrinology, 1998).
What to know before considering it
Half-life determines dosing schedule, but it does not determine appropriateness for an individual. A clinician will consider your baseline labs, health history, and goals when deciding on the timing and frequency of any protocol. Never adjust a dosing schedule without clinician guidance — altering timing based on convenience rather than pharmacokinetics can undermine the protocol’s intended effect.
The Halftime POV
Half-life is one of those concepts that looks like pharmacology-class detail but has very practical consequences for how you actually live with a protocol. A once-weekly injection is a different lifestyle commitment than a nightly one. Understanding the pharmacokinetics helps you have a real conversation with your clinician about protocol design — not just about what to take, but about how it will fit into your actual schedule.
Related reading:
FAQ
Q: What is peptide half-life? A: Half-life (t½) is the time required for the plasma concentration of a compound to decrease by 50% from its peak. It determines how frequently a peptide must be dosed to maintain a therapeutic effect. Most unmodified peptides have short half-lives — minutes to a few hours — because the body’s peptidases break them down rapidly.
Q: Why does CJC-1295 with DAC have a longer half-life than regular CJC-1295? A: Adding a Drug Affinity Complex (DAC) allows the CJC-1295 molecule to bind to albumin in the bloodstream, dramatically slowing clearance. The non-DAC version has a half-life of roughly 30 minutes; the DAC version has a half-life of approximately 6–8 days, as documented by Teichman et al. in the Journal of Clinical Endocrinology & Metabolism, 2006.
Q: Does a longer peptide half-life mean a better protocol? A: Not necessarily. A longer half-life changes the dosing schedule and the concentration curve over time, but appropriateness depends on the goal. Pulsatile GH secretion — which mimics natural physiology — may be better served by short-acting peptides dosed at specific times. The right half-life profile is determined by a clinician based on your labs and goals.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.
Sources
- Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 2006.
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998.
